Heart Failure Congress 2024 has unveiled 8 Late-breaking trial sessions for 2024. 

Heart Failure 2024 will take place at the Lisbon Congress Center in May. Access the full Programme here. 

Late breaking clinical trials I

Saturday 11th May, 08:30 – 09:30am

• Intravenous iron therapy with ferric carboxymaltose results in a rapid and sustained rise in myocardial iron content through a non-canonical pathway: a translational study
• Timing of Cardio-Kidney Protection with SGLT2 Inhibitors: Insights from Four Large-scale Placebo-Controlled Outcome Trials
• Impact of a remote monitoring program on all-cause mortality of patients with heart failure: National, real-world evidence of the TELESAT study
• The consistency of the treatment benefit of remote hemodynamic monitoring in chronic heart failure: a predefined subgroup analysis of the randomised clinical Trial MONITOR-HF
• Suspected de novo heart failure in outpatient care: high mortality and morbidity rates (REVOLUTION HF)

Late breaking clinical trials: medical therapy

Saturday 11th May, 13:45 – 14:45pm

• A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure
• A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
• Readily available urinary sodium analysis in patients with acute decompensate Heart Failure
• DEA-HF: The heart failure diuresis efficacy comparison study
• Low-dose administration of carperitide for Acute Heart Failure

Late breaking clinical trials: registries

Sunday 12th May, 08:30 – 09:30am

• Cardiovascular burden of the amyloidogenic V1421 transthyretin variant in black individuals
• Incidence and prognosis of respiratory failure in acute heart failure
• Sex-specific clinical outcomes and healthcare resource utilization in the 5 years following hospitalization for heart failure
• Glucagon-like peptide-1 receptor agonist in obese heart failure with preserved ejection fraction and type 2 diabetes mellitus
• Portuguese Heart Failure Prevalence Observational Study

Late breaking clinical trials: devices

Sunday 12th May, 10:45am – 12:15pm

• Correlation of the non-invasive cardiopulmonary management wearable device with measures of congestion in Heart Failure study
• A Prospective, Multi-center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients
• REducing Lung congestIon symptoms using the v-wavE shunt in adVancEd Heart Failure
• Cardiac Resynchronization Therapy DeliveRy Guided by Non-Invasive Electrical and Venous Anatomy Assessment (CRT-DRIVE) Clinical Trial
• Benefits of upgrading right ventricular to biventricular pacing in heart failure patients with atrial fibrillation
• Low mortality in AdaptResponse compared to historical pharmacological and CRT trials in heart failure with reduced ejection fraction
• Differential effects of inter-atrial shunt treatment on cardiac structure and function in patients with heart failure reduced vs preserved ejection fraction: data from RELIEVE-HF Trial
• Transvenous phrenic nerve stimulation to treat central sleep apnea in heart failure

Late Breaking Clinical trials: drugs and disease management

Sunday 12th May, 13:45 – 14:45pm

• The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes: a pre-specified analysis of the EMPACT-MI trial
• Contemporary guideline-directed medical therapy sequencing and titration in de novo, worsening, and chronic heart failure: first data from the TITRATE-HF study
• First implementation results from the Trial for Evaluating Accelerated Guideline-Directed Medical Therapy for Heart Failure
• Pragmatic Urinary Sodium-based algoritHm in Acute Heart Failure trial
• Efficacy of hypertonic saline therapy in ambulatory patients with heart failure

Late Breaking Clinical trials: further analyses and baseline characteristics

Monday 13th May, 08:30 – 09:30am

• Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF: insights from the STEP-HFpEF programme
• Design and baseline characteristics of REALIZE K: a placebo-controlled randomized-withdrawal trial of sodium zirconium cyclosilicate for hyperkalaemia management in patients with HF and reduced EF
• Effect of IV iron in patients with heart failure with preserved ejection fraction
• Design and baseline characteristics of FINE-HEART: an integrated pooled analysis of finerenone in >19,000 participants across 3 phase III trials of HF & CKD
• Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: baseline characteristics of patients in the RESHAPE-HF2 trial

Late Breaking Clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy

Monday 13th May, 13:45 – 14:45pm

• Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial
• Semaglutide therapy and diuretic use in obesity-related HFpEF: insights from the STEP-HFpEF programme
• Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial
• Enhancing exercise response in obstructive HCM: insights from aficamten's impact on patients with obstructive hypertrophic cardiomyopathy in SEQUOIA-HCM
• Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM

Late breaking clinical trials II

Tuesday 14th May, 08:30 – 09:30am

• Transendocardial injection of autologous expanded CD34+ Stem Cells (ProtheraCytes) promotes reverse cardiac remodeling in patients with left ventricular dysfunction after acute myocardial infarction
• Bio-ADM as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure; data from STRONG-HF
• Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial
• Cardiac reverse remodeling in the trial of accelerated guideline-directed medical therapy for Heart Failure (TEAM-HF)
• Suspected de novo heart failure in outpatient care: high overall healthcare costs (REVOLUTION HF)